It was reported that SNORD114-1 regulates the cell cycle transition mediated by the Rb/p16 pathway in AML.20 Some studies on the sno/scaRNA profile have revealed dysregulated snoRNAs in different subtypes of leukemia, including SNORD109A, SNORD64, SNORD107, SNORD116-18, SNORA31, SNORA6, SNORA62, SNORA71C, SNORA70F, SNORA74A, SNORD56, and SNORD1A.67,68 Among the dysregulated snoRNAs, SNORD116-18, SNORA70F, SNORA74A, SNORD56, and SNORD1A have been associated with shorter PFS for CLL patients.67 These snoRNAs are promising targets for leukemia therapy. This evidence concerns the gene SNORD116 and leukemia.